Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

TIBSOVO is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for TIBSOVO solidifies Servier’s leadership in mutant IDH inhibition BOSTON, Oct. 24, 2023 /PRNewswire/ — Servier, a leader in oncology committed to…